CLEVELAND, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel, February 8-9, 2010, in New York City. The conference will provide a forum to discuss breakthrough therapeutic developments and issues that affect the biotech industry.
Dr. Gil Van Bokkelen, chairman and chief executive officer, is scheduled to present on Monday, February 8, 2010, at 1:00 p.m. EST. Investors and other interested parties may listen to a live, audio webcast at: http://www.veracast.com/webcasts/bio/ceoinvestor2010/33101524.cfm. A replay will be available one hour after the conclusion of the live event until May 11, 2010.
About the BIO CEO & Investor Conference
Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. This year’s conference will feature corporate presentations from more than 120 companies, workshops featuring leading experts on specific therapeutic and technology topics, plenary and panel sessions on timely business issues and industry trends, many opportunities to schedule one-on-one meetings, as well as numerous networking opportunities. For more information, visit www.ceo.bio.org.
About Athersys
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease. The Company is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE®). Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, including Pfizer, Angiotech and Bristol-Myers Squibb, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products.
The Athersys, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4548
CONTACT: Athersys, Inc.
William (B.J.) Lehmann, J.D., President and
Chief Operating Officer
(216) 431-9900
bjlehmann@athersys.com
In-Site Communications
Investor Relations:
Lisa M. Wilson
(917) 543-9932
lwilson@insitecony.com
Pure Communications, Inc.
Media Relations:
Dan Budwick
(973) 271-6085
dan@purecommunicationsinc.com
